BI 655066/ABBV-066 (Risankizumab) Versus Ustekinumab and Placebo Comparators in a Randomized Double Blind trIal for Maintenance Use in Moderate to Severe Plaque Type Psoriasis (UltIMMa-1)
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 21 Jul 2017
At a glance
- Drugs Risankizumab (Primary) ; Ustekinumab
- Indications Plaque psoriasis
- Focus Registrational; Therapeutic Use
- Acronyms UltIMMa-1
- Sponsors AbbVie; Boehringer Ingelheim
- 15 Sep 2016 Status changed from recruiting to active, no longer recruiting.
- 17 Jun 2016 Planned End Date changed from 1 Nov 2017 to 1 Sep 2017.
- 17 Jun 2016 Planned primary completion date changed from 1 Feb 2017 to 1 Dec 2016.